AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase III study titled A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy. The study aims to assess the efficacy and safety of subcutaneous anifrolumab in reducing skin disease in patients with cutaneous lupus erythematosus (CLE) who do not respond to antimalarial treatments.
The intervention being tested is anifrolumab, a combination product administered via subcutaneous injection, intended to improve skin conditions in CLE patients. Participants in the study will receive either anifrolumab or a placebo, with the placebo group switching to anifrolumab after 23 weeks.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model, involving two stages with similar designs but different sample sizes. The primary purpose is treatment, with masking applied to both participants and investigators.
The study began on June 29, 2024, with the last update submitted on July 23, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
This study update could positively impact AstraZeneca’s stock performance by bolstering investor confidence in its pipeline for treating autoimmune diseases. The collaboration with Parexel and the focus on a challenging patient population underscore AstraZeneca’s commitment to innovation in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.